Pfizer files lawsuits against Novo over $9B Metsera bid, challenging 30-month timeline. Court hearing Tuesday as deadline ...

Dow Jones Top Company Headlines at 5 AM ET: Saudi Aramco's Net Profit Rises on Higher Production, Oil Prices | BP ... Third-quarter profit rose compared with the prior three-month period but declined ...

Novo Nordisk's new CEO, Mike Doustdar, is under significant pressure as the company contends with declining stock prices, ...

Novo Nordisk’s sharp decline may have opened the door for a massive rebound here’s why investors are watching its ...

Novo Nordisk's new CEO is set to face intense investor scrutiny this week as the Wegovy-maker shakes up its board and pursues ...

On Monday, major U.S. indexes showed mixed performance — the Dow Jones Industrial Average slipped nearly 0.5% to 47,336.68, ...

Hims & Hers continues to sell compounded semaglutide, the active ingredient in Novo’s Wegovy and Ozempic drugs, and these ...

Novo Nordisk asserts its acquisition of Metsera won't pose antitrust problems as it competes with Pfizer for dominance in the ...

The latest buyout Novo Nordisk is trying to pull off is putting it in a direct confrontation with another beaten-down ...

What's better than investing in a stock with a promising outlook? Investing in a beaten-down stock with a promising outlook.

Novo Nordisk made a surprise bid for Metsera to boost its weight-loss market lead, trading at just 12x 2026 EPS. Read why NVO ...

Dow Jones Top Company Headlines at 9 PM ET: Why Pfizer Can Still Prevail in the Obesity Fight With Novo Nordisk | BDO's ... Novo Nordisk and Pfizer are showing some desperation in their gloves-off ...